The NFκB Responsive Luciferase Reporter MCF7 Stable Cell Line is derived from MCF7 and stably expresses a firefly luciferase reporter gene under the control of NFκB response elements, enabling sensitive and quantitative monitoring of NF-κB signaling pathway activity.
 
MCF7 cells are a widely used model in cancer biology and cellular signaling research due to their robust growth characteristics and responsiveness to pathway modulation. This stable reporter cell line provides a convenient and reliable platform for studying NFκB-mediated transcriptional regulation and signaling dynamics in response to various biological stimuli and therapeutic compounds.
 
NFκB is a key transcription factor involved in the regulation of immune and inflammatory responses, cell proliferation, differentiation, survival, and apoptosis. In response to stimuli such as cytokines, oxidative stress, free radicals, ultraviolet irradiation, and bacterial or viral antigens, NFκB becomes activated and translocates from the cytoplasm to the nucleus, where it binds to specific response elements and regulates downstream gene expression. Dysregulation of NFκB signaling has been associated with cancer, chronic inflammation, autoimmune disorders, and infectious diseases, making NFκB an important target for biomedical research and drug discovery.
 
Signosis developed this NFκB luciferase reporter MCF7 stable cell line through lentiviral transduction using an NFκB-responsive luciferase reporter construct. Stable clones were subsequently screened and validated based on TNF-α-induced luciferase activity to ensure robust and reproducible NFκB pathway responsiveness.